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Extracellular vesicles (EVs) are important in normal physiology and are altered in various pathologies. EVs produced by different cells
are antigenically different. Since the majority of EVs are too small for routine flow cytometry, EV composition is studied predominantly in
bulk, thus not addressing their antigenic heterogeneity. Here, we describe a nanoparticle-based technique for analyzing antigens on single
nano-sized EVs. The technique consists of immuno-capturing of EVs with 15-nm magnetic nanoparticles, staining captured EVs with
antibodies against their antigens, and separating them from unbound EVs and free antibodies in a magnetic field, followed by flow analysis.
This technique allows us to characterize EVs populations according to their antigenic distribution, including minor EV fractions. We
demonstrated that the individual blood EVs carry different sets of antigens, none being ubiquitous, and quantified their distribution. The
physiological significance of antigenically different EVs and their correlation with different pathologies can now be directly addressed.
From the Clinical Editor: This study reports a nanoparticle-based technique for analyzing antigens on single nano-sized extracellular
vehicles (EV). The technique consists of immuno-capturing of EVs with 15-nm magnetic nanoparticles, followed by staining the captured
EVs with antibodies and separating them via a magnetic field, followed by flow analysis. This technique enables studies of antigenic
properties of individual EVs that conventionally can only be studied in bulk.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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http://dx.doi.org/10.1016/j.nano.2014.09.020cation because different proteins, lipids and RNAs are specifically
incorporated into these vesicles, which can be targeted to remote
cells through receptor–ligand interactions1,3. Release of EVs was
reported to change in pathologies (reviewed in4,5) including
cancer6-9, neurological, hematological 9, cardiovascular10,11,
autoimmune and rheumatologic12 diseases, and viral infection13-15.
Since various cells supplying EVs express different antigens,
EVs produced by these cells are antigenically different. For example,
CD81, a member of the tetraspanin superfamily, is expressed on
several cell types including hepatocytes and B lymphocytes16;
CD63, another member of this family, is expressed on activated
platelets, endothelium, fibroblasts, and macrophages17,18; CD41, an
integrin alpha chain 2b, is a heterodimeric integralmembrane protein
expressed on platelets, megakaryocytes, and hematopoietic stem
cells19; CD31, a platelet endothelial cell adhesion molecule, is
expressed on vascular endothelial cells, platelets, naive T cells,
monocytes, and neutrophils20.
Analyses of bloodEVcomposition,which have been performed
predominantly in bulk, have revealed the presence of various
cellular antigens in EVs21 but could not reflect the distribution of
these antigens on individual EVs although such distribution may
report on physiological conditions of the donor22,23.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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of small particles like EVs. Several attempts to overcome this
limitation have been reported, including the use of single nanometric
particle enumerators24, microfluidics-based cytometers25, and
cytometers optimized to improve light scattering collection26,27.
While these methods have confirmed the diversity of EV size and
quantity28,29, in most cases they failed to address the compositional
diversity of EVs.
While EVs can become visible in flow cytometers upon their
staining with fluorescent antibodies, it is difficult to distinguish
them from free fluorescent antibodies. Recently it was reported
that by using a BD Influx flow cytometer with wide-angle
forward scatter it is possible to visualize small fluorescent
particles, including EVs labeled with fluorescent antibodies30,31.
Here, we report on the analysis of surface proteins on single
nano-sized (b300 nm) EVs with a newly developed nanoparticle-
based technique. We used a commercial flow cytometer and
magnetic nanoparticles to isolate fluorescence-labeled EVs and to
separate them from non-bound fluorescent antibodies. We
demonstrate that the blood EVs are highly heterogeneous in surface
proteins, with none of the analyzed antigens being ubiquitous.
Our analysis revealed the distribution of several antigens and their
combinations on single vesicles.
Methods
EV preparation and labeling
Microvesicles derived from the SUPT1-CCR5 CL.30 cell line
were purified on sucrose gradients and non-specifically labeled with
eitherAlexaFluor 4885CMaleimide (50 μM)orAlexaFluor 6335C
Maleimide (38 μM)as described32 (kindly providedbyDr. J. Lifson).
Normal blood plasma from the NIH blood bank was collected
in several 8-ml tubes with sodium citrate (3.2%); the first tube
was discarded to avoid collecting EVs released by platelets
activated by venipuncture. Collection tubes were centrifuged at
3000g for 15 min to obtain platelet-poor plasma (PPP), followed
by a thromboplastin treatment and by the isolation of EVs as
described in the Exoquick protocol. Alternatively, we used PPP,
enrichedwith EVs by centrifugation with 100 KMWCO (Amicon
Millipore, Billerica, MA) concentrators (8-fold enrichment).
Coupling of monoclonal antibodies to magnetic nanoparticles
Carboxyl-terminated magnetic iron oxide nanoparticles
(MNPs; 1 mg of 15-nm particles) (Ocean NanoTech, Springdale,
AR) were coupled to mouse–anti-human monoclonal antibodies
recognizing different EV antigens. The three antibodies used
alternatively for coupling to MNPs were anti-CD81 (eBioscience,
San Diego, CA), anti-CD63, and anti-CD31 (BioLegend,
San Diego, CA), as previously described33. Briefly, 1 mg of
MNPs was incubated in 200 μl of activation buffer supplemented
with 1.7 mM1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hy-
drochloride and 0.76 mM N-hydroxysulfosuccinimide (Sulfo-NHS)
for 10 min at room temperature. After activation, 500 μl of coupling
buffer was added to the MNPs, followed by the addition of 1 mg of
the purified antibody. After 2-hours in a thermo mixer at room
temperature, the reaction was stopped with 10 μl of quenching
solution, transferred to a 5 ml propylene round-bottom tube(12 × 75-mm, BD Falcon) and inserted into SuperMag Separator™
magnetic separator.Weperformed twowashesusing aSuperMAG-01
magnetic separator (Ocean NanoTech) at 4 °C. The coupled MNPs
were suspended in 2 ml of storage buffer and stored at 4 °C at a
concentration of 0.5 mg/ml of iron oxide (based on the initial iron
oxide concentration provided by the manufacturer).
Capture and detection of EVs with nanoparticles
To visualize the anti-EV–antibody–MNP complexes, MNPs
coupled to anti-EV antibody were incubated with 5 μg of Alexa
Fluor 488-labeled goat anti-mouse IgG Fab fragments (Zenon
anti-mouse IgG, Life Technologies, Carlsbad, CA). To separate
free Fab fragments from the bound ones the preparation was
washed twice with 300 μl of PBS on a 100-kD nanosep centrifugal
device (Pall Corporation, Port Washington, NY) and recovered
in its initial volume.
Next, a 106 excess of Zenon-labeled MNPs coupled to an
antibody against an EV antigen were incubated with EVs 1 hour at
4 °C. Various combinations of monoclonal antibodies against
other cellular antigens on EVs: anti-CD31–PE, anti-CD81–PE
(BioLegend, San Diego, CA), and anti-CD41–APC (BD, Pharmi-
gen, San Diego, CA) were added for 15 min at room temperature.
EV–MNPs–antibodies complexes were separated on
μMACS magnetic columns (Miltenyi Biotech, Auburn, CA) in
a high magnetic field generated by a OctoMacs magnet (Miltenyi
Biotech). The columns were washed three times with a washing
buffer consisting of PBS, 0.5% BSA, and 2 mM EDTA; the
complexes were eluted off the magnet in 2 × 200 μl of PBS and
fixed in 1% formaldehyde in PBS. To evaluate the efficiency of
separation of unbound antibodies, to EV-MNPs complexes, we
added fluorescent isotype control antibodies (which should not
bind to EVs), and acquired this mixture on the flow cytometer
and compared with the same preparation subjected to a magnetic
column separation. There was less than 1% of non-specific
fluorescent antibodies co-purified with the EVs (Figure S1).
Separated MNPs-EV complexes were subjected to flow
analysis. AccuCheck beads (50 μl; Life Technologies) were
added to each elution tube to evaluate the volume acquired for
flow analysis. On the basis of this volumetric measurement, the
number of events can be recalculated as EV concentrations.
iMFI, which reports on the integrated fluorescence intensity
by combining the relative amount of positive events with the
mean fluorescence intensity (MFI) of these events34,35 was
calculated as suggested iMFI = (MFI) × (P); where P is the
fraction of positive events.
We used LSRII (BDBiosciences, San Jose, CA) flow cytometer
equipped with 355-, 407-, 488-, 532- and 638-nm laser lines.
Compensation beads (BD) were used to perform compensa-
tion controls.
Detection of EVs by ELISA
Nunc MAXISORP plates (Nalgene- Nunc, Penfield, New
York, USA) were coated with 50 μl of a 4 μg/ml solution of
anti-CD81 antibody (clone 5A6, BioLegend) in PBS. The plate
was washed and blocked overnight with 100 μl of antibody/Antigen
Conjugate Diluent/Blocker (Poly-HRP) (Fitzgerald Industries
International, Acton, MA) and washed with PBS. EVs were purified
Figure 1. Detection of single EVs. Isolated EVs from SUPT1-CCR5 CL.30 cells were divided into two fractions, one labeled with Alexa Fluor 633 (A) and the
other with Alexa Fluor 488 (B). These fractions were mixed, captured with anti-CD81MNPs (C), and analyzed with flow cytometer. Aggregates were visualized
as dual-color events. Note that only about 8% of events represent aggregates. A representative experiment out of four is shown.
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treated with anti-CD81MNPs and separated on a magnetic column.
The flow-through fraction was diluted three times in PBS and
incubated in duplicate wells in the coated plate. A remaining aliquot,
representing the EVs input was diluted three times in PBS and
incubated in duplicate wells of the coated ELISA plate. Following a
1-hour incubation, the plate was washed with PBS and incubated
with 50 μl of biotinylated anti-CD81 antibody at a 1 μg/ml. The
plate was washed with PBS and incubated with 50 μl of 0.2 μg/ml
solution of Poly-HRP 20 (Fitzgerald Industries International).
Following four washes, the plate was incubated with 50 μl of
TMB (Fitzgerald Industries International) for 20 minutes and read at
367 nm with a Tecan Safire II (Tecan, Austria) using Magelan 6.0.
Results are reported as optical density at 367 nm.
Statistical analysis
Descriptive statistics were calculated with Excel. Comparisons
of the proportions of captured EVs, either pre-labeled or not, were
performed with aχ2 test using JMP 9.0 (SAS Institute, Cary, NC).
The results are presented as means ± standard errors of the mean
(SEM), and n, the number of replicates, is indicated. CV, the
coefficient of variation, was calculated by expressing the standard
deviation as % of the mean. The numbers of EVs captured at
different MNP-to-EV ratios were modeled using JMP software.
TheGompertz 3P sigmoid curve gave the best data fit andwas used
to estimate the optimal ratio by inverse prediction function.Results
For analysis of individual EVs we (i) coupled magnetic
nanoparticles (MNPs) to mouse anti-human antibodies against
EV surface antigens, (ii) stained MNPs with fluorescent
anti-mouse IgG1 Fab fragments, (iii) captured EVs with
antibody-coupled MNPs, (iv) stained the resultant complexes
with fluorescent “detection” antibodies against antigens ofinterest, (v) separated EV-MNP-detection antibody complexes
from free antibodies in a strong magnetic field using magnetic
columns, and (vi) analyzed complexes with a flow cytometer set
to be triggered by fluorescence, rather than by light scattering.
We first analyzed individual EVs in a reductionist model
of cloned cells releasing vesicles into the culture medium and
then studied the distribution of individual EVs in the blood of
healthy individuals.
Flow analysis of SUPT1-CCR5CL.30 cell line-generated EVs
First, we investigated whether the EVs captured by antibody-
coupled MNPs and detected as events in flow analysis represent
individual vesicles.We divided EVpreparations into two fractions,
one labeled with Alexa Fluor 488 and the other with Alexa Fluor
633; combined these two differentially labeled EVs in equal
quantities; incubated them with MNPs coupled to anti-CD81
antibodies (a common EV antigen21); separated captured EVs in a
magnetic field and analyzed them using a flow cytometer. EV
aggregates bound to MNPs should appear as events positive for
both fluorophores. On average, only 9.6% ± 0.5% (n = 4) of
events represented EV aggregates. Thus, about 90% of
MNP-bound EVs observed in flow analysis represent single
vesicles (Figure 1). This is in stark contrast with results from large
4.5 μm Exosome Dynabeads®, which bind multiple EVs that can
only be further analyzed collectively (see Figure S2).
Next, we determined the MNP-to-EV ratio that maximizes
EV capture, using anti-CD81 capture MNPs at concentrations
varying from 34 × 107/μl to 34 × 109/μl and Alexa Fluor
633-labeled EVs at concentrations varying from 18 × 103/μl to
87 × 105/μl. For each experiment performed at a given
MNP-to-EV ratio, we purified the complexes on a magnetic
column and enumerated these labeled EVs both in the fraction
that was retained on the magnetic column and in the fraction that
was not (flow-through). We found that, at different ratios of
MNPs to EVs, these fractions vary, and at a ratio above
2.3 × 105 [as evaluted with a regression curve (Figure S3)], we
capture 95% of EVs towards which MNPs are targeted. In
Figure 2. Efficiency of the MNP capture assay. Alexa Fluor 633-labeled EVs isolated from SUPT1-CCR5 CL.30 cells (A and B) or blood plasma EVs (C) were
captured with anti-CD81MNPs and isolated on amagnetic column. The non-captured (flow-through) fraction was captured again with anti-CD81MNPs and isolated
on a magnetic column (B) or adsorbed on a CD81 coated ELISA plate (C).A and B: histograms of the flow analysis of captured (A) and re-captured (B) EVs. The
numbers of events acquired in the same volume (9.7 μl) as evaluatedwith AccuCheck are shown.C: ELISAmeasurement of CD81 in the total EVs population (input)
and in the fraction non-captured with anti-CD81 MNPs (flow-through). Note that the fraction not captured in the first run constitutes less than 1% of the originally
captured EVs as evaluated with flow cytometry and about 6% as evaluated by ELISA. A representative experiment out of two to three is shown.
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the ratio to EVs higher than 106 capturing essentially all the EVs
of interest.
To evaluate the efficiency of the assay, using volumetric
controlled flow analysis, we enumerated labeled EVs in the initial
preparation, in the fractions of EVs captured with anti-CD81, and in
the flow-through. The latter were subjected to another capture
procedure.We captured almost all CD81-carryingEVs present in the
preparation, since a second capture procedure of the flow-through
fraction of EVs with anti-CD81 MNPs resulted in recapture of less
than 1% (Figure 2, A and B) of the original EVs. To confirm this
high capture efficiency, we evaluated with ELISA the amounts of
CD81 in the initial preparation of EVs isolated from blood plasma
and in the flow-through fraction after capturing EVs with anti-CD81
MNPs. In this assay, less than 6% of the initial amount of CD81 was
revealed in the flow through-fraction (Figure 2, C).
Flow analysis of EVs isolated from blood plasma
Empowered by the results of analysis of EVs in cell culture
supernatant, we analyzed single EVs in blood plasma. EVs were
isolatedwith Exoquick, capturedwithMNPs, stainedwith detection
antibodies, and purified in a magnetic field. We added AccuCheck
beads to estimate the sample volume acquired in order to accuratelydetermine EV concentrations. The total number EVs in our plasma
was ~3500 per μl, as evaluated for plasma samples in which EVs
were stained with the fluorescent lipidic dye DiI (data not shown).
This number is within the earlier reported range (see 22,23), although
it varies between plasmas from different donors.
We further analyzed the composition of plasma EVs by
capturing them with MNPs coupled to antibodies recognizing
EVs-specific antigens and staining them with detection antibod-
ies. The specificity of the capture of plasma EVs with MNPs
coupled to EVs-specific antibodies was demonstrated by
comparison with MNPs coupled to non-specific control
antibodies (Figure 3, A and B). This specificity of capture is
reflected in the integrated MFI (iMFI)34,35, which combines the
relative amount of positive events with the mean fluorescence
intensity of these events: 5574 and 70 for CD81, and 2074 and
22 for CD41 for specific staining and isotype control,
respectively. In addition, we used isotype control antibody to
verify the specificity of detection of EV antigens (Figure 3, D
and F). Using this approach, we demonstrated that the fraction of
captured EVs depended on the capture-antigen and for CD81
constituted about 30% of total EVs, while CD31/CD81 and
CD31/CD41 EVs represented smaller fractions (Figure 3, C and
E). The specific capture of EVs by MNPs allowed us to focus on
Figure 3. Specificity of capture and staining of plasma EVs. EVs isolated from platelet poor plasma were incubated with anti-CD31 MNPs (A) or with MNPs
coupled to irrelevant antibodies (B) and stained with anti-CD81 PE and anti-CD41 APC antibodies. EVs captured with anti-CD31MNPs were stained with either
anti-CD81 PE (C) or anti-CD41APC antibodies (E), or stained with labeled isotype control PE mouse IgG1κ (D) and APC mouse IgG1κ (F) antibodies.
Presented are the numbers of events acquired in the same volume (10 μl) as evaluated with AccuCheck. One representative experiment out of four (A and B) and
one out of five (C and D) are shown. Note the specificity of both capture with MNPs bound to specific antibodies compared to capture with MNPs bound to
isotype control antibodies (A vs. B), and the specificity of staining of captured EVs with specific antibodies compared to isotype control antibodies (C vs. D and
E vs. F).
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CD31. At first, we tried to identify these EVs in the large pool of
vesicles that express CD81, which was defined earlier as one of the
prevalent EV antigens 21. However, when we stained these
vesicles for CD31, their numbers were only slightly above the
isotype control and not significantly different from it (5 ± 2 EVs/μl
for specific staining for CD81 + CD31+ EVs vs. 2.7 ± 1.2/μlisotype control staining, n = 4, P = 0.3). In contrast, when we first
captured CD31-expressing EVs with anti-CD31MNPs, and stained
them for CD81 we reliably identified CD81 co-expressing EVs,
which were present on average at a concentration of 101 ± 32/μl
(n = 4), which is significantly higher than when EVs were stained
with an isotype control antibody (2.3 ± 1.5/μl,P = 0.03) (Figure 3,
C and D, iMFI 6451 and 104 for C and D, respectively).
Figure 4. The lack of steric hindrance between MNPs and free antibodies. EVs isolated from platelet poor plasma were separated into two fractions. One fraction
was captured with anti-CD31 MNPs labeled with Alexa Fluor 488 and stained with anti-CD41 APC-labeled antibody (A); the other was first stained for CD41
with the same antibody and then captured with anti-CD31 MNPs (C). Isotype controls: B and D. Presented are the numbers of events acquired in the same
volume as evaluated with AccuCheck. A representative experiment out of two.
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On average, per microliter there were 80 ± 27 CD31-captured EVs
that expressedCD41 (n = 5). In isotype control, on average therewere
3.2 ± 1.0 positive events/μl (n = 5) (Figure 3, E and F, iMFI 2070
and 107 for E and F, respectively). To test whether boundMNPs can
shield other EV surface antigens by steric hindrance, we compared the
amount of EVs when we first captured EVs with anti-CD31 MNPs
and then stained with anti-CD41 antibodies (Figure 4, A and B) with
the amount detected when we first stained EVs with anti-CD41
antibodies and then captured them with anti-CD31 MNPs (Figure 4,
C andD). The results were similar (P = 0.12), suggesting that MNPs
bound to CD31 do not shield this EV antigen. Also, similar
concentrations of EVs were evaluated when we either captured them
with anti-CD63 MNPs and then stained with anti-CD41 antibodies
or first stained with anti-CD41 antibodies and then captured with
anti-CD63 MNPs (data not shown).
To analyze the fine distribution of CD31-carrying EVs, we
stained them with both anti-CD41 and anti-CD63 detection
antibodies. Among CD31-captured EVs that expressed CD41,
on average 80.6 ± 5.7% were positive for CD63 (n = 7), while
among CD31-captured EVs that expressed CD63, on average
41 ± 5.8% (n = 7) co-expressed CD41. The absolute amountsof these EVs were donor-dependent: in samples from different
donors the concentrations of CD31+ CD41 + EVs in plasma
varied between 24/μl and 170/μl.
Flow analysis of EVs in blood plasma
The data presented in the previous section were obtained on
EVs isolated with Exoquick. Although this is a widely used
method for EV isolation36, we decided to modify our protocol to
exclude this isolation step and to analyze individual EVs directly
from blood plasma.
Platelet poor plasma (PPP) was incubated with MNPs
coupled to antibodies against EV surface antigens. Figure 5
illustrates the result of such analysis with EVs captured with
anti-CD63 MNPs and stained for CD41. 0.1 ml of 8-fold
concentrated PPP was enough to capture EVs that carry CD41
(Figure 5, A) in amounts that were far in excess of non-specific
events (Figure 5, B). To estimate the reproducibility of our
analysis and of the variability between different donors, we
performed this assay on samples from two donors, each in
triplicate. In this analysis, the concentration of CD63-captured
CD41-positive EVs was 87 ± 6/μl in one patient and 26 ± 2/μl
in another patient (CVs 12.1 and 13.2%, respectively). Thus, our
Figure 5. Direct analysis of blood plasma EVs. Concentrated platelet poor plasma was incubated with anti-CD63 MNPs. Captured EVs were stained with
APC-labeled anti-CD41 antibodies (A) or with isotype control APC mouse IgG1κ (B), purified in a magnetic field and analyzed with flow cytometer. Presented
are the numbers of events acquired in the same volume (9.7 μl) as evaluated with AccuCheck. A representative experiment of triplicates sets on platelet poor
plasma from two donors is shown.
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at both low and high EV counts.Discussion
The physiological role of the vesiculation of cell membranes
was emphasized about 30 years ago37,38. However, it is only
recently that cell-derived EVs have attracted much attention,
since it is now understood that EVs generation is a normal
physiological process involved in cell–cell communications39,40.
Although EVs have been found in all body fluids, the exact functional
difference between various EVs has not been yet established.
Recently, it was reported that blood EV spectra are changed
in various diseases, in particular in cardiovascular disease.
For example, it was reported22,23 that EV shedding is increased
with the exacerbation of cardiovascular disease, but not with
the atherosclerotic burden in stable patients. These and other
reports41,42 attracted attention to the association of blood EVs
with particular medical conditions.
Until recently, studies were focused on EVs of 0.5 to 1 μm in
diameter, which were studied predominantly with flow cytom-
etry developed for cells. However, recent analysis of EVs with
high-resolution atomic force microscopy revealed that vesicles
of such size constitute only a small percentage of the total EV
population. The rest of the EVs are of approximately 100 nm43
and thus are too small to be visible with regular light microscopy
or to be detected with routine flow cytometry.
Unfortunately, contemporary methods predominantly analyze
EVs in bulk. Such an approach ignores the importance of
particular fractions of EVs by diluting the sought-after specific
signal in the noise of the overall output. These bulk methods
include biochemical analysis of EV extracts as well as
immunochemical analysis of EVs adsorbed on various particles.
In particular, a method of adsorbing EVs on microbeads, such asExosome Dynabeads® followed by staining with fluorescent
antibodies and analysis with flow cytometer, has been
described44. However, numerous EVs are attached to each
microbead, and this method thus constitutes essentially another
bulk analysis. Such analyses have helped identifying antigens in
EV preparations but have failed to analyze their presence on
individual EVs, as confirmed in the present work (Figure S2).
Most of the methods used to monitor and analyze individual
EVs have been restricted to the evaluation of the number and
physical parameters of individual EVs and have included atomic
force microscopy, dynamic light scattering, nanoparticle tracking
analysis, evaluation of particle ζ-potential, as well as other
methods45. While these methods establish the heterogeneity of
individual EVs, new high-throughput methods are necessary to
characterize the composition of individual EVs as flow
cytometry did for individual cell analysis.
The diversity of molecules carried by EVs stems from the fact
that they are shed into blood by diverse cells. Using EVs as
biomarkers reflecting the origin and physiological status of the
producing cells in norm and in diseases requires distinguishing
EV subpopulations on the basis of their individual cellular
markers against the background of the output of all cells
irrelevant to the phenomenon studied.
Here, we analyzed the antigenic make-up of single EVs and
quantified diverse subpopulations of EVs according to the
antigens they carry. In contrast to most published data, we
focused our analysis on small EVs below 300 nm, which
constitute the vast majority of blood EVs43 and which because of
their small size cannot be analyzed with routine flow cytometry.
Our analysis is based on using 15-nm MNPs, which, through
a “capture” antibody against EV surface protein, bind to EVs. In
these complexes of single EVs bound to magnetic nanoparticles,
various EVs antigens can be revealed with specific fluorescent
antibodies. The magnetic properties of the complexes allow us to
separate them from unbound antibodies in a magnetic field, thus
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generate. Earlier, we applied MNPs to the analysis of individual
HIV-1 virions33.
Separation of EVs in a high-energy magnetic field using the
magnetic properties of MNPs that capture them is crucial since,
unlike conventional cellular analysis in which the washing of
free-floating antibodies can be skipped by use of a proper FSC
threshold, the inability of conventional cytometers to detect the
light scattering of sub-microscopic vesicles does not allow the
distinction between vesicle-bound and free antibodies. In the
absence of separation from free antibodies, fluorescent EVs
would be lost in a sea of antibodies and their aggregates (Figure S1).
Use of MNPs allows the complete separation of EVs carrying a
particular antigen from non-bound fluorescent antibodies within
10 min, while separation in sucrose gradients requires a 14- to
20-hour centrifugation30,31.
Although, with magnetic columns we efficiently separated
MNPs-EV complexes bound to fluorescent detection antibodies
from unbound antibodies, we did not rely exclusively on the
purity of the final preparation but applied an additional marker to
exclude unbound antibodies: we labeled MNPs with fluorescent
Fab against the capture antibody, thus introducing another
fluorescent molecule into the MNPs-EV complexes. The
antibody–EV–MNPs complexes are then identified on the
basis of their positivity for at least two fluorescent markers,
while free antibodies are not visualized even if they had
contaminated the final preparation.
Another important part is the flow cytometer setting. For cell
analysis, these instruments are set to trigger on the light scattered
when a cell crosses the laser beam. EV-MNPs complexes are too
small to trigger a flow cytometer with light scattering, so the
trigger event has to be set on a fluorescence channel.
CD81 has been reported to be common for certain types for
EVs21, and we used this antigen to capture EVs generated by
lymphocytic cells in culture. We found that to maximize EV
capture, we need more than five-order excess of MNPs. At the
MNP-to-EV ratio of 106 used in our experiment, about 99% of
EVs bind to MNPs and are retained in the magnetic field. As with
the immune staining of cells when antibodies are added in vast
excess but only a small fraction actually binds to their antigens,
the majority of MNPs does not bind to EVs but remains free.
These MNPs do not interfere with the analysis of MNPs–EV
complexes, which unlike free MNPs carry several fluorophores.
As far as the EV-bound MNPs are concerned, they do not seem
to be a steric hindrance preventing free antibodies from binding
to their antigens. Indeed, reversing the order of EV capture with
MNPs and staining with a detection antibody did not significantly
affect the estimated quantity of EVs.
To prove that the recorded events predominantly represent
individual EVs, we labeled EVs with two different fluorophores,
mixed these two fractions, and captured them with anti-CD81
MNPs. Aggregates of EVs would predominantly be seen as
events positive for both fluorophores. Such events represented a
small fraction of the total, whereas about 90% of the events
reflected individual EVs. Thus, unlike most of the other EVs
studies that characterize them in bulk, here we analyzed the
antigenic composition of individual cell-derived and blood-derived
EVs and quantitated their diversity.We found that although CD81 is a common antigen, it is not
ubiquitous: it is associated with less than 30% of blood EVs.
These numbers reflect the true presence of CD81-carrying EVs
in the preparation, rather than the efficiency of capture. Indeed,
recapture of the EVs that were not captured in the first run
revealed that we might have missed less than 1% of
CD81-carrying EVs. The high efficiency of capture was
confirmed when we evaluated the non-captured CD81-carrying
EVs with ELISA. Thus, EVs show a large degree of
heterogeneity, not only when they are derived from different
cell types as found in plasma, but also when they are derived
from cloned cells; a result that could not be obtained from a bulk
analysis of EVs.
While it may seem possible to capture the majority of EVs
through a highly prevalent antigen such as CD81, minor
fractions of CD81-carrying EVs, e.g., CD31-bearing, are
difficult to identify because of a low signal-to-noise ratio. In
particular, when we focused on CD31-carrying blood EVs
among CD81-captured EVs, these EVs were barely above the
non-specific background. In contrast, when we used anti-CD31
MNPs we reliably identified them, visualizing CD81 on their
surfaces as well as CD63 and CD41. We reliably detected ~5
EVs per microliter of concentrated plasma. To what concentra-
tion of EVs in the original sample this number corresponds
depends on how much the original sample was concentrated. In
our experiments we concentrated 5 to 8 times.
Unlike most published EV analyses, here we not only
registered the diversity of EVs in their expression of different
antigens but also quantified their distribution. Moreover, this
analysis can be performed not only on EVs released by cells in
culture, but also directly on blood plasma EVs. With MNPs
coupled to antibodies against EV antigens, it is possible to focus
on EVs that constitute a small fraction of EVs present in normal
blood plasma. Moreover, we were able to evaluate the
distribution of other antigens in these minor EV fractions. In
particular, when we captured CD31-carrying EVs, we found that
about half of these EVs co-expressed CD41 and CD63. Although
CD63 is a highly prevalent antigen, our fine analysis of antigen
distribution demonstrated that within the sensitivity limit of our
cytometer, it is not carried by approximately 20% of the
CD31+ CD41 + EVs; thus these EVs form a separate fraction.
In conclusion, here we performed a fine analysis of single
blood EVs according to the distribution of their antigens. We
demonstrated that the blood EV population is a mosaic, with
various EVs carrying different combinations of antigens. None
of these antigens can be claimed to be present on all EVs. These
results would be impossible to obtain in a bulk analysis, which
reports only on the general presence of particular antigens in EV
preparations. Moreover, since many of the plasma membrane
antigens are common to more than one cell type, individual
EVs should be characterized by combinations rather than by
single antigens.
Because of the reproducibility of our analysis of distributions
of individual blood EVs according to the combinations of
antigens they carry, it is now possible to relate these distributions
to the medical condition of an individual donor, as well as to
search for EV antigenic patterns common to particular diseases.
The physiological significance of antigenically different
497A. Arakelyan et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 489–498individual EVs and their correlation with different pathologies
can now be directly addressed.Contribution
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